AIA
PCRX icon

Affinity Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Affinity Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,125
Closed -$207K – 170
2023
Q4 		$207K Sell
6,125
-3,620
-37% -$106K 0.14% 171
2023
Q3 		$299K Hold
9,745
– – 0.19% 156
2023
Q2 		$390K Sell
9,745
-1,965
-17% -$81.2K 0.23% 149
2023
Q1 		$478K Hold
11,710
– – 0.26% 141
2022
Q4 		$452K Buy
11,710
+99
+0.9% +$4.82K 0.21% 149
2022
Q3 		$618K Hold
11,611
– – 0.32% 113
2022
Q2 		$677K Sell
11,611
-640
-5% -$41.9K 0.33% 105
2022
Q1 		$935K Sell
12,251
-3,385
-22% -$226K 0.38% 93
2021
Q4 		$941K Buy
15,636
+77
+0.5% +$4.25K 0.38% 99
2021
Q3 		$871K Hold
15,559
– – 0.39% 90
2021
Q2 		$944K Hold
15,559
– – 0.43% 86
2021
Q1 		$1.09M Sell
15,559
-950
-6% -$67.9K 0.4% 71
2020
Q4 		$988K Sell
16,509
-410
-2% -$24K 0.4% 66
2020
Q3 		$1.02M Sell
16,919
-370
-2% -$21.5K 0.45% 60
2020
Q2 		$907K Hold
17,289
– – 0.43% 63
2020
Q1 		$580K Buy
17,289
+5,570
+48% +$231K 0.3% 72
2019
Q4 		$531K Hold
11,719
– – 0.19% 87
2019
Q3 		$446K Hold
11,719
– – 0.14% 95
2019
Q2 		$510K Buy
+11,719
New +$498K 0.15% 82

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Affinity Investment Advisors's PCRX Position: Q1 2024 in Review

Affinity Investment Advisors sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 6,125 shares — an estimated $207K sold.

Affinity Investment Advisors first reported a position in PCRX in Q2 2019 and held it in 19 quarters. The position peaked at $1.09M in Q1 2021. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

  • Affinity Investment Advisors reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
  • Affinity Investment Advisors sold 6,125 Pacira BioSciences shares in Q1 2024, an estimated $207K.
  • Affinity Investment Advisors first reported a position in Pacira BioSciences in Q2 2019 and held it in 19 quarters.
  • Affinity Investment Advisors's Pacira BioSciences position peaked at $1.09M in Q1 2021.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Affinity Investment Advisors's 13F filing for Q1 2024, filed 3 May 2024.